Başkent University Faculty of Medicine, Department of Ophthalmology, İstanbul, Turkey
Neoretina Eye Clinic, İstanbul, Turkey
Turk J Ophthalmol. 2022 Apr 28;52(2):119-124. doi: 10.4274/tjo.galenos.2021.83648.
To evaluate the efficacy and safety of heavy silicone oil as an endotamponade in patients with recurrent or complicated retinal detachment and macular hole.
Nineteen eyes of 19 patients who underwent heavy silicone oil endotamponade for different indications were included in the study and evaluated by retrospective chart review. At each visit, patients underwent detailed ophthalmological examination and anatomical and functional outcomes, silicone oil emulsification, intraocular inflammation, presence of proliferative vitreoretinopathy, preoperative and postoperative visual acuity, and postoperative complications were recorded.
The study included 19 eyes of 19 consecutive patients: 13 women (68.4%) and 6 men (31.6%). The patients' median age was 60 years (interquartile range [IQR]: 44-70 years) and the median follow-up time was 19 months (IQR: 9-31 months). Indications for heavy silicone oil endotamponade were recurrent retinal detachment in 11 eyes (57.8%), inferior retinal detachment in 5 eyes (26.3%), inferior rhegmatogenous retinal detachment, recurrent macular hole in 2 patients (10.5%), and macular hole in 1 patient (5.2%). Median best corrected visual acuity was 2 logMAR (IQR: 1-2.6) preoperatively and 0.99 logMAR (IQR: 0.4-2) postoperatively (p<0.001). Postoperative anatomical success was achieved in all patients. Densiron 68 was used for endotamponade in 14 patients (73.7%), Densiron XTRA in 3 patients (15.8%), and AlaHeavy 1.07 in 2 patients. Heavy silicone oil emulsification was observed in only 3 patients (15.8%).
Although heavy silicone oil has limitations as an endotamponade, such as intraocular pressure increase, emulsification, intraocular inflammation, and the risk of complications during removal, it is a safe and effective alternative in eyes requiring inferior retinal tamponade for indications like proliferative vitreoretinopathy and recurrent macular holes.
评估重硅油作为内眼填充物在复发性或复杂性视网膜脱离伴黄斑裂孔患者中的疗效和安全性。
本研究回顾性分析了 19 例(19 只眼)不同适应证行重硅油内眼填充的患者资料。每次就诊时,患者均接受详细的眼科检查,并记录解剖学和功能结果、硅油乳化、眼内炎症、增殖性玻璃体视网膜病变的存在、术前和术后视力以及术后并发症。
本研究共纳入 19 例(19 只眼)连续患者,其中女性 13 例(68.4%),男性 6 例(31.6%)。患者中位年龄 60 岁(四分位距 [IQR]:44-70 岁),中位随访时间 19 个月(IQR:9-31 个月)。行重硅油内眼填充的适应证为:11 只眼(57.8%)为复发性视网膜脱离,5 只眼(26.3%)为下方视网膜脱离,2 例(10.5%)为下方孔源性视网膜脱离伴复发性黄斑裂孔,1 例(5.2%)为黄斑裂孔。术前最佳矫正视力中位数为 2 logMAR(IQR:1-2.6),术后为 0.99 logMAR(IQR:0.4-2)(p<0.001)。所有患者术后解剖学均成功。14 例(73.7%)患者使用了 densiron 68,3 例(15.8%)患者使用了 densiron XTRA,2 例(10.5%)患者使用了 AlaHeavy 1.07。仅 3 例(15.8%)患者出现重硅油乳化。
尽管重硅油作为内眼填充物存在眼压升高、乳化、眼内炎症以及在取出过程中发生并发症的风险等局限性,但对于需要下方视网膜填塞的患者,如增殖性玻璃体视网膜病变和复发性黄斑裂孔,它仍是一种安全有效的选择。